Your browser doesn't support javascript.
loading
Validation of MSIntuit as an AI-based pre-screening tool for MSI detection from colorectal cancer histology slides.
Saillard, Charlie; Dubois, Rémy; Tchita, Oussama; Loiseau, Nicolas; Garcia, Thierry; Adriansen, Aurélie; Carpentier, Séverine; Reyre, Joelle; Enea, Diana; von Loga, Katharina; Kamoun, Aurélie; Rossat, Stéphane; Wiscart, Corentin; Sefta, Meriem; Auffret, Michaël; Guillou, Lionel; Fouillet, Arnaud; Kather, Jakob Nikolas; Svrcek, Magali.
Afiliação
  • Saillard C; Owkin France, Paris, France. charlie.saillard@owkin.com.
  • Dubois R; Owkin France, Paris, France.
  • Tchita O; Owkin France, Paris, France.
  • Loiseau N; Owkin France, Paris, France.
  • Garcia T; Medipath, Fréjus, France.
  • Adriansen A; Medipath, Fréjus, France.
  • Carpentier S; Medipath, Fréjus, France.
  • Reyre J; Medipath, Fréjus, France.
  • Enea D; Department of Pathology, Saint-Antoine Hospital - Sorbonne Université, AP-HP, Paris, France.
  • von Loga K; Owkin France, Paris, France.
  • Kamoun A; Owkin France, Paris, France.
  • Rossat S; Medipath, Fréjus, France.
  • Wiscart C; Owkin France, Paris, France.
  • Sefta M; Owkin France, Paris, France.
  • Auffret M; Owkin France, Paris, France.
  • Guillou L; Owkin France, Paris, France.
  • Fouillet A; Owkin France, Paris, France.
  • Kather JN; Else Kroener Fresenius Center for Digital Health, Technical University Dresden, Dresden, Germany.
  • Svrcek M; Department of Medicine I, University Hospital Dresden, Dresden, Germany.
Nat Commun ; 14(1): 6695, 2023 11 06.
Article em En | MEDLINE | ID: mdl-37932267
ABSTRACT
Mismatch Repair Deficiency (dMMR)/Microsatellite Instability (MSI) is a key biomarker in colorectal cancer (CRC). Universal screening of CRC patients for MSI status is now recommended, but contributes to increased workload for pathologists and delayed therapeutic decisions. Deep learning has the potential to ease dMMR/MSI testing and accelerate oncologist decision making in clinical practice, yet no comprehensive validation of a clinically approved tool has been conducted. We developed MSIntuit, a clinically approved artificial intelligence (AI) based pre-screening tool for MSI detection from haematoxylin-eosin (H&E) stained slides. After training on samples from The Cancer Genome Atlas (TCGA), a blind validation is performed on an independent dataset of 600 consecutive CRC patients. Inter-scanner reliability is studied by digitising each slide using two different scanners. MSIntuit yields a sensitivity of 0.96-0.98, a specificity of 0.47-0.46, and an excellent inter-scanner agreement (Cohen's κ 0.82). By reaching high sensitivity comparable to gold standard methods while ruling out almost half of the non-MSI population, we show that MSIntuit can effectively serve as a pre-screening tool to alleviate MSI testing burden in clinical practice.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Colorretais / Instabilidade de Microssatélites Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Colorretais / Instabilidade de Microssatélites Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article